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ese authors contributed equally to this manuEpidemiological studies have shown that estrogens have protective effects in cardiovascular diseases,
even though the results from human clinical trials remain controversial, while most of the animal ex-
periments conﬁrmed this effect, but the detailed mechanism remains unclear. In this study, we found
that estradiol (E2) treatment signiﬁcantly increases the expression of mitochondrial superoxide dis-
mutase (SOD2) in mice and in vitro in human aorta endothelial cells. Further investigation shows that E2
up-regulates SOD2 through tethering of estrogen receptor (ER) to Sp1 and the increased binding of Sp1 to
GC-box on the SOD2 promoter, where ERα responses E2-mediated gene activation, and ERβ maintains
basal gene expression level. The E2/ER-mediated SOD2 up-regulation results in minimized ROS gen-
eration, which highly favors healthy cardiovascular function. Gene therapy through lentivirus-carried
endothelium-speciﬁc delivery to the vascular wall in high-fat diet (HFT) mice shows that the SOD2 ex-
pression in endothelial cells normalizes E2 deﬁciency-induced ROS generation with ameliorated mi-
tochondrial dysfunction and vascular damage, while SOD2 knockdown worsens the problem despite the
presence of E2, indicating that E2-induced SOD2 expression plays an important vasculoprotective role. To
our knowledge, this is the ﬁrst report for the mechanism by which E2 improves cardiovascular function
through up-regulation of SOD2 in endothelial cells. In turn, this suggests a novel gene therapy through
lentivirus-carried gene delivery to vascular wall for E2 deﬁciency-induced cardiovascular damage in
postmenopausal women.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).Introduction
Many epidemiological studies have shown that post-
menopausal women who use estrogens are at lower risk for car-
diovascular disease (CVD) than those who do not use estrogens,
suggesting a beneﬁcial action of endogenous estrogen [1–3]. The
vasculoprotective effect of estrogen has been demonstrated clearly
in many animal models to prevent atherosclerosis development,
such as in apolipoprotein E-deﬁcient (ApoE /), low density li-
poprotein receptor-deﬁcient (LDLr/) mice [4–6] and high-fat
diet (HFD) mice [7]. However, the large randomized controlled
clinical trials did not conﬁrm the preventive action of estrogens
against coronary heart disease (CHD) [8]. This discrepancy has
been attributed to the importance of age in the action of estrogens
on endothelial function [9], the differences of endogenousB.V. This is an open access article
Liu),
script.estrogen and conjugated equine estrogens (CEEs) and the differ-
ences between oral and transdermal drug delivery [10].
Estrogens, primary examples of female sex steroids, control
cellular growth, differentiation, female reproductive functions, and
cardiovascular systems [11]. Estradiol (E2), the main form of es-
trogen, interacts with two estrogen receptors (ER), ERα and ERβ
[12], which exert their effects through diverse signaling pathways
that mediate the genomic and nongenomic events [13,14]. Mem-
brane-initiated effects regulate ion channels and signal transduc-
tion pathways through post-translation modiﬁcation or protein–
protein interaction [15,16], while genomic effects regulate gene
transcription either through the direct binding of ER dimers to
estrogen response elements (ERE) on related gene promoters [17]
or by cross-talk or tethering to other transcription factors, such as
activation protein-1 (AP1) [18], NFκB [19] or speciﬁcity protein-1
(Sp1) [20].
Excessive reactive oxygen species (ROS) generation plays
an important role in a number of cardiovascular diseases, in-
cluding hypertension, atherosclerosis and myocardial ischemia/
reperfusion (I/R) injury [21]. The antioxidant enzyme SOD2under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
Z. Liu et al. / Redox Biology 3 (2014) 88–99 89(mitochondrial superoxide dismutase) catalyzes dismutation of
mitochondrial O2 , it has been reported to have a protective ef-
fect on vascular function. SOD2 deﬁciency results in increased ROS
generation with subsequent mitochondrial dysfunction and oxi-
dative stress [22,23]. SOD2 was used for the gene therapy in the
animal model of CVD, and the results showed that SOD2 gene
transfer reverses vascular dysfunction only in the absence of
atherosclerosis plaque [21,24], this may indicate that the en-
dothelial cells play a dominant role in vasculoprotective action as
long as the endothelial cells irreversibly lose the function, the
SOD2 therapy will not work, this is consistent with the recent
ﬁndings [4].
In an effort to identify the molecular mechanism for the E2-
mediated vasculoprotective effect, we have found that the SOD2
expression is signiﬁcantly increased in endothelial cells under the
E2 treatment. Further investigation shows that E2 up-regulates
SOD2 through tethering of ER to Sp1 and the increased binding to
GC-box on the SOD2 promoter, where both ERα and ERβ play an
essential role in this kind of regulation. SOD2 up-regulation results
in minimized ROS generation, which largely favors cardiovascular
function. Gene therapy through lentivirus-carried endothelium-
speciﬁc delivery to vascular wall in high-fat diet (HFD) mice shows
that the SOD2 expression normalizes E2 deﬁciency-induced ROS
generation with ameliorated cardiovascular damage. We conclude
that E2 improves cardiovascular function through up-regulation of
SOD2 expression on vascular wall.Experimental procedure
Materials and methods
Primary human aorta endothelial cells (HAECs, obtained from
Lonza) were conditionally immortalized by hTERT expression with
extended life span [25,26]. Cells were maintained in EBM-2
medium (from Lonza) with all the supplements. The HAECs were
treated with ethanol (vehicle), 100 nM E2 (from Sigma), or E2 plus
10 mM ICI 182,780 (ICI, from Tocris Bioscience) for 48 h, then the
cells were harvested for further analysis. The antibodies for β-actin
(sc-47778), 3-nitrotyrosine (3-NT, sc-55256), SOD2 (sc-30080),
Sp1 (sc-59) and Sp3 (sc-644) were obtained from Santa Cruz
Biotechnology, and the antibodies for ERα (ab37438) and ERβ
(sc-137381) were purchased from Abcam. Nuclear extracts were
prepared using the NE-PER Nuclear and Cytoplasmic Extraction
Reagents Kit (Pierce Biotechnology). Protein concentration was
measured by Coomassie Protein Assay Kit (Pierce Biotechnology)
using BSA as a standard. Plasmid DNA was transfected by Lipo-
fectamine™ reagent (Invitrogen). siRNA against Sp1, Sp3, ERα and
ERβ or non-speciﬁc siRNA (from Ambion) were transfected using
Oligofectamine reagent (Invitrogen) according to the manu-
facturers' instructions.
Construction of plasmids and vectors
Human genomic DNA was prepared from HAECs. The SOD2
gene promoter (2 kb upstream of the transcription start site plus
ﬁrst exon) was ampliﬁed by PCR and subcloned into pGL3-basic
vector. To localize estrogen response element (ERE) on the SOD2
promoter, the related deletion constructs were generated by PCR
methods and the indicated ERE or GC box mutation plasmids were
generated using the Site-directed Mutagenesis Kit from Promega.
The cDNA for SOD2 (from Open Biosystems) was subcloned into
pcDNA3.1 for generation of expression plasmids. All the vectors
were veriﬁed by sequencing, and the detailed information is
available upon request.RT reaction and real-time quantitative PCR
Total RNA from treated cells was extracted by RNeasy Mini Kit
or RNeasy Micro Kit (Qiagen), and the RNAwas reverse transcribed
by Omniscript RT kit (Qiagen). Real-time quantitative PCR was run
on iCycler iQ (Bio-Rad) with the Quantitect SYBR green PCR kit
(Qiagen). PCR was performed by denaturing at 95 °C for 8 min,
followed by 45 cycles of denaturation at 95 °C, annealing at 60 °C,
and extension at 72 °C for 10 s, respectively. 1 ml of each cDNA was
used to measure target genes. The results were normalized by β-
actin.
Luciferase reporter assay
1.0105 Cells were seeded in a 6-well plate with completed
medium to grow until they reach 80% conﬂuence. The related lu-
ciferase reporter plasmids (3 mg) and 0.2 mg pRL-CMV-LucRenilla
plasmid (from Promega) were transiently cotransfected. Some
experiments need to cotransfect the siRNA oligonucleotides. After
12 h transfection, the cells were washed and treated for 48 h with
either ethanol control, 100 nM E2 or E2 plus 10 mM ICI 182,780.
The cells were harvested and the luciferase activity assays were
carried out using the Dual-Luciferase™ Assay System (Promega),
and transfection efﬁciencies were normalized using a co-
transfected Renilla plasmid.
Western blotting
Cells were lysed in ice-cold lysis buffer (0.137 M NaCl, 2 mM
EDTA, 10% glycerol, 1% NP-40, 20 mM Tris base, pH 8.0) plus pro-
tease inhibitor cocktail (Sigma), and the proteins were separated in
10% SDS-PAGE and further transferred to PVDF membrane, the
membrane was incubated with appropriate antibodies, washed
and incubated with HRP-labeled secondary antibodies, then the
blots were visualized by ECLþplus Western Blotting Detection
System (Amersham), and the blots were quantitated by IM-
AGEQUANT, and the ﬁnal results were normalized by β-actin.
Chromatin immunoprecipitation (ChIP)
The procedure used here is described by Metivier et al. with
minor modiﬁcation [27]. Brieﬂy, treated cells were washed and
crosslinked using 1% formaldehyde for 20 min and terminated by
0.1 M glycine. Cell lysates were sonicated and centrifuged. 500 mg
protein were pre-cleared by BSA/salmon sperm DNA plus pre-
immune IgG and a slurry of Protein A Agarose beads. Im-
munoprecipitations were performed with the indicated anti-
bodies, BSA/salmon sperm DNA and a 50% slurry of Protein A
agarose beads. Input and immunoprecipitates were washed and
eluted, then incubated with 0.2 mg/ml Proteinase K for 2 h at 42 °C
followed by 6 h at 65 °C to reverse the formaldehyde crosslinking.
DNA fragments were recovered by phenol/chloroform extraction
and ethanol precipitation. No bands were observed after im-
munoprecipitation with pre-immune IgG. A 150 bp fragment
from the SOD2 promoter was ampliﬁed by real-time PCR (qPCR).
Measurement of ROS generation
Treated cells were seeded in a 96-well plate and incubated with
10 mM CM-H2DCFDA (Invitrogen) for 45 min at 37 °C, then the
intracellular formation of reactive oxygen species (ROS) was
measured at excitation/emission wavelengths of 485/530 nm
using an FLx800 microplate ﬂuorescence reader (Bio-Tek). The
data were normalized as arbitrary units [28]. Levels of an oxidative
marker 3-nitrotyrosine was measured by western blots.
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Biotin-labeled sense and antisense oligonucleotides with frag-
ment (270 to 138) of human SOD2 promoter were synthe-
sized, annealed and puriﬁed as the DAPA probe. 200 mg nuclear
extracts in binding buffer (60 mM KCl, 12 mM HEPES, pH 7.9,
4 mM Tris–HCl, pH 7.5, 5% glycerol, 0.5 mM EDTA, 1 mM DTT and
protease inhibitors) were pre-cleared by 3 mg of scrambled double-
strand DNA supplemented with pre-equilibrated Tetralink™ Avi-
din Resin (Promega). The pre-cleared nuclear extracts were further
incubated with 2 mg of DAPA probe at 4 °C for 2 h with gentle
rotation, then 20 ml pre-equilibrated Tetralink™ Avidin Resin was
added to incubate for another 1 h. Beads were pelleted and wa-
shed with buffer, then boiled for 5 min in SDS-PAGE gel loading
buffer for western blotting analysis.
Generation of Tie2-driven SOD2 expression lentivirus
The mouse genomic DNA was puriﬁed from C57BL/J6 wild type
mouse, and the endothelium-speciﬁc Tie2 promoter (2000 up-
stream plus exon 1) was ampliﬁed by PCR, fused with the mouse
SOD2 cDNA (obtained from Open Biosystems), then they were
subcloned into pLVX-Puro vector (from Clontech), and the Tie2-
empty, or Tie2-SOD2 lentivirus, was expressed through Lenti-X™
Lentiviral Expression Systems (from Clontech) according to man-
ufactures’ instructions. The virus was further puriﬁed, con-
centrated and titrated to reach 2108 MOI/mL for the tail vein
injection to infect the experimental mice.
Generation of Tie2-driven SOD2 shRNA lentivirus
The shRNA for scramble or SOD2 were synthesized and fused
with mouse Tie2 promoter (2000 upstream plus exon 1), then
subcloned into pLVX-shRNA2 vector (from Clontech), and the Tie2-
scramble (CTL), or Tie2-shSOD2 lentivirus was expressed through
Lenti-X™ shRNA Expression Systems (from Clontech) according to
manufactures' instructions.
In vivo mice experiments
The animal study protocol was reviewed and approved by the
Institutional Animal Care and Use Committee of our institute. The
female C57BL/6J mice were housed 4 or 5 per cage on a 12:12-h
light-dark cycle and were given phytoestrogen-free commercial
rodent chow and water ad libitum on arrival. At 4 weeks of age,
the mice received either sham or bilateral ovariectomy (OVX)
surgery with high-fat diet (HFD, 60% calories from fat, Research
Diets Cat. #D12492) through the rest of the experiments. At
6 weeks, mice received treatments consisting of 90-day time re-
lease pellets (Cat #: NE-121, from Innovative Research of America)
that were implanted subcutaneously via a 3-mm incision on the
dorsal aspect of the neck. Hormone pellets contained 0.72 mg ofTable 1
Details and conditions for the mice treatment.
Animal group Sham/CTL OVX/CTL OVX/
n 13 15 14
Sham/OVX surgery Sham OVX OVX
Vehicle/E2 pellet Vehicle Vehicle E2
Lentivirus injection Tie2-empty Tie2-empty Tie2-
Plasma E2 (pg/ml) 4779 1473 1057
Body weight (g) 36.271.2 42.671.1 37.67
Total cholesterol (mg/dl) 146.1±14.3 279.4±13.4 139.7
Triglyceride (mg/dl) 128.4±8.7 208.6±10.4 129.7E2, while placebo pellets contained the same matrix as the E2
pellets but with no hormone [4,29]. The mice also received tail
vein injection of 150 ml lentivirus (2108 MOI) for either Tie2-
empty (CTL), Tie2-↑SOD2 or Tie2-shSOD2 continuously twice
within a 2-day interval. At 19 weeks, the old estradiol release
pellets were replaced by the new pellets to achieve continuous E2
treatment. At 32 weeks, the overnight-fasted mice were anesthe-
tized, the body weight was measured, the tissues, including heart,
aorta, liver, kidney and hypothalamus, were isolated for mRNA
analysis, and the blood was collected for measuring plasma es-
trogen (E2) and lipids, including total cholesterol and triglyceride.
The MECs were isolated from the heart and aorta and cultured in
vitro for the further analysis of SOD2 activity and mitochondrial
function. The aortas were isolated to measure in vivo superoxide
release and vessel tension. In some treatments, the hearts or
aortas were dissected and snap-frozen in OCT compound. 10 mm
sections were cut by clean microtome and mounted on PEN-
membrane slides (2.0 mm, Leica) for isolation of mouse endothelial
cells (MECs) using Laser Capture Microdissection (LCM) for mRNA
analysis. The details for those mice and their treatments are shown
in Table 1.Plasma analysis for E2 and lipids
E2 level were analyzed on plasma from individual mice ob-
tained at sacriﬁce using the E2 ELISA kit (Cat #: ADI-900-174 from
Enzo). The total cholesterol (TC) and triglyceride (TG) in plasma
were measured using a GM7 Micro.-Stat Rapid Multiassay Analy-
ser (Analox) according to manufactures' instructions.In vivo superoxide release
The superoxide anion (O2) release from the aorta was de-
termined by a luminol–EDTA–Fe enhanced chemiluminescence
(CL) system supplemented with dimethyl sulphoxide–tetrabutyl-
ammonium chloride (DMSO–TBAC) solution for extraction of re-
leased O2 from tissues as described previously [28]. The su-
peroxide levels were calculated from the standard curve generated
by the xanthine/xanthine oxidase reaction.Isolation of mouse endothelial cells (MECs)
Isolation of endothelial cells from the heart and aortas was
performed following the previously described procedure [30]. The
isolated endothelial cells were further characterized by immuno-
ﬂuorescence staining with an antibody to the von Willebrand
factor (vWF). The passage P3–P5 was used for further in vitro
analysis.E2 OVX/↑SOD2 OVX/shSOD2 OVX/shSOD2/E2
17 13 16
OVX OVX OVX
Vehicle Vehicle E2
empty Tie2-↑SOD2 Tie2-ShSOD2 Tie2-shSOD2
13 1374 1575 101715
1.5 40.771.4 41.871.3 38.971.0
±12.1 265.3±14.9 281.4±15.4 144.3±15.3
±7.9 205.1±9.7 211.7±14.6 133.4±9.3
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The mitochondrial fraction was prepared from the above iso-
lated MECs using differential centrifugation [31] with minor
modiﬁcation. Brieﬂy, treated cells were harvested and cell pellets
were homogenized in the buffer containing 15 mM Tris buffer,
pH 7.6; 0.25 M sucrose; 1 mM MgCl2; 1 mM EDTA; 1 mM dithio-
threitol (DTT) and the mixture of protease inhibitor cocktail (Sig-
ma). Cell homogenates were centrifuged at 800g at 4 °C for 8 min,
subsequent supernatants were further centrifuged at 16,000g at
4 °C for 15 min. The pellets were resuspended in homogenization
buffer and centrifuged at 16,000g at 4 °C for 20 min. The sub-
sequent pellets were resuspended and collected as the mi-
tochondrial fractions for the SOD2 activity assay.Evaluation of SOD2 activity
The SOD activity from the mitochondrial fraction of MECs was
measured as described previously [32]. Brieﬂy, a stable O2
source was generated through the conversion action of xanthine
oxidase (XOD) from xanthine and was mixed with chemilumi-
nescent (CL) reagents to achieve a stable light emission. The SOD2
sample injection can scavenge O2 and the subsequent decrease
of chemiluminescent response is proportional to the SOD2 activity.
This system can have a detection limit of 0.001 U/ml with the
linear range of 0.03–2.00 U/ml. The results were normalized by
protein concentration and were expressed as Units/mg proteins
(U/mg).Measurement of mitochondrial function
The intracellular ATP level was determined by the luciferin/
luciferase-induced bioluminescence system. An ATP standard
curve was generated at concentrations of 1012–103 M. In-
tracellular ATP levels were calculated and expressed as nmol/mg
protein. The Mitochondrial Membrane Potential (MMP, ΔΨm) was
measured by 3,3′-dihexiloxadicarbocyanine (DiOC6), cells were
trypsinized, resuspended and incubated with 0.2 mM DiOC6 for
20 min at 37 °C, and cells were further treated with 1 mM propi-
dium iodide for 30 min. The DiOC6 ﬂuorescence was measured by
FACS at an excitation/emission wavelength of 485/500 nm [28].
The caspase-3 activity was determined by the ApoAlert caspase
assay kit (Clontech). Treated cells were harvested and 50 mg of
proteins were incubated with the ﬂuorogenic peptide substrate
Ac-DEVD-7-amino-4-triﬂuoromethyl coumarin (AFC). The initial
rate of free AFC release was measured using an FLx800 microplate
reader (Bio-Tek) at excitation/emission wavelengths of 380/
505 nm, and enzyme activity was calculated as pmol/min/mg [28].Monitoring of vascular function
The vascular function was evaluated by measurement of vessel
tension. The vessel tension in mice aortas was measured in a
vessel myograph system (from DMT). The aortas were isolated and
immersed in Krebs bicarbonate buffer (118 mmol/l NaCl,
4.7 mmol/l KCl, 25 mmol/l NaHCO3, 1.2 mmol/l KH2PO4, 1.2 mmol/
l MgSO4, 2.5 mmol/l CaCl2, and 5 mmol/l glucose) and then sus-
pended by 2 tungsten wires mounted in vessel myograph
system. To study vasodilator responses, the rings were pre-
constricted with phenylephrine, and the acetylcholine (Ach,
1010–104 M) was injected at the plateau of the phenylephrine-
induced contraction [33].Statistical analysis
The data were given as mean7standard deviation (S.D.), all
experiments were performed at least in triplicate unless otherwise
indicated. All analyses were performed using GraphPad Prism
6 statistical software. The student unpaired t test or ANOVA were
used to determine statistical signiﬁcance of different groups, a P
value o0.05 was considered signiﬁcant.Results
Female mice have signiﬁcant higher expression of SOD2 than male
mice in the cardiovascular system
We ﬁrst measured the mRNA expression of SOD2 in the car-
diovascular system of mouse, including the heart and aorta, and
found that the female mice have higher SOD2 mRNA levels than
male mice, and ovariectomized (OVX) female mice's expression
levels were similar to those of male mice, and the expression was
restored to wild type females when OVX female was treated by E2
(see Fig. 1a). We also measured the gene expression from mouse
aorta endothelial cells isolated by Laser Capture Microdissection
(LCM), it showed that female mice have around 2 times higher
expression than male mice (Fig. 1b).
E2-induced SOD2 expression is restored by ER inhibitor in HAECs
We next measured E2-induced gene expression in human aorta
endothelial cells (HAECs). In Fig. 1c, the mRNA expression of SOD2
increased around 2.6-fold under the E2 treatment, while this effect
was completely blocked by the treatment of estrogen receptor (ER)
inhibitor-ICI 182,780, indicating that E2 induces the gene expres-
sion through ER activation. We also measured the protein ex-
pression of SOD2 (see Fig. 1c), consistent with the changes of
mRNA level, E2 treatment increased SOD2 protein expression,
while ICI 182,780 treatment blocked the effect of E2.
E2-induced SOD2 transcriptional-response element is located at the
area of  300 to 100 with multiple GC box binding sites on the
SOD2 promoter
The mechanism of E2-induced SOD2 expression was further
investigated. To localize the regulatory elements required for
transcriptional expression of SOD2 gene by E2 treatment, the
progressive 5′ promoter deletion constructs, including 2000,
1500, 1000, 500, 400, 300, 200, 100, 0 were gen-
erated (numbered according to Ensembl Transcript ID:
ENST00000337404). In Fig. 2a, the E2-induced SOD2 transcrip-
tional-response element is located in the area of  300 to 100
on the SOD2 promoter. Transcription factor databases (TESS) re-
vealed several potential binding motifs in this area, including 5 GC
boxes (Sp1 binding site) and 3 ERE1/2 binding sites as shown in
Fig. 2b (upper panel). The possible involvement of these motifs on
the E2-induced SOD2 transcriptional expression was explored
using a series of single mutants in luciferase constructs at the area
of  300 to 100. As shown in Fig. 2b down panel, all of the 5 GC-
box single mutants signiﬁcantly decreased the E2-induced SOD2
activation, whereas none of the ERE1/2 motif showed any effect.
This indicates that the multiple GC box binding motif located
at  300 to 100 area is required for E2 responsiveness of the
SOD2 promoter.
E2-induced SOD2 expression is due to the E2-induced ER activation
and the subsequent increased binding of ERα/Sp1 and decreased
Fig. 1. The expression of SOD2 is regulated by E2 and ER. (a, b) 6-week-old age-matched male and female C57BL/6J mice received either Sham or ovariectomy (OVX) surgery
in the presence of either vehicle (Veh) or E2 for another 2 weeks, then sacriﬁced, the mRNA expression was analyzed. (a) The tissues of heart and aorta were isolated for
SOD2 mRNA analysis. (b) The mouse aorta endothelial cells (MAECs) were isolated using laser capture microdissection for SOD2 mRNA analysis. n, Po0.05, vs male group.
(c, d) The primary HAECs were treated by either ethanol control (CTL), 100 nM E2 or E2 plus 10 mM ICI 182,780 (ICI) for 2 days, the cells were harvested for gene expression.
(c) mRNA by qPCR. (d) Representative bands and quantitative results for SOD2 protein by Western blotting. n, Po0.05, vs CTL group. n¼4, data are expressed as mean7SEM.
Fig. 2. E2-induced SOD2 transcriptional-response element is located at the area of 300 to 100 with multiple GC box binding sites on the SOD2 promoter. (a) The
conditional immortalized HAECs were transiently transfected by either SOD2 full length or deletion reporter plasmids, then treated by either control (CTL) or 100 nM E2 for
2 days, and the reporter activities were measured. n, Po0.05, vs pSOD2-2000 group. (b) The cells were transfected by either wild type (WT), ERE1/2 or GC-box. mutation
plasmids on the SOD2 promoter, and treated by CTL or E2, and the reporter activities were measured. n, Po0.05, vs WT group. n¼4, data are expressed as mean7SEM.
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Fig. 3. E2/ER activation induces increased binding of ERα/Sp1 and decreased binding of ERβ/Sp3 to multiple GC box on the SOD2 promoter. (a) The nuclear extracts from the
above treated cells were immunoprecipitated (IP) by Sp1, then immunoblotted by Sp1, ERα or ERβ respectively. (b) The quantitation results for a. (c) The biotin-labeled
oligonucleotides (fragment of 270 to 138 on the SOD2 promoter) were used for DNA pull-down assay in the nuclear extracts from treated cells, and the pull down
proteins were blotted by Sp1, Sp3, ERα and ERβ, respectively. (d) The quantitation results for c. (e) The primary HAECs were treated by either CTL or E2 for 2 days, the cells
were then harvested for ChIP analysis using the antibodies of ERα, ERβ, Sp1 and Sp3, respectively, and the SOD2 promoter in the range of 100 to 262 was ampliﬁed by
qPCR. n, Po0.05, vs CTL group. n¼4, data are expressed as mean7SEM.
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the SOD2 promoter
We ﬁrst did the immunoprecipitation (IP) using Sp1 antibody
from treated cellular nuclear extracts, then immunoblotted (IB) by
ERα and ERβ. We found that E2 treatment signiﬁcantly increased
the association of Sp1 with ERα, but decreased the association of
Sp1 with ERβ (see Fig. 3a, b). On the other hand, we obtained
negative results from IP/IB for Sp3/ERβ, indicating that either Sp3
does not directly bind with ERβ, or the interaction of Sp3 and ERβ
is too weak to be detected. We then investigated the binding
ability of those transcription factors on the above multiple GC-box
of SOD2 promoter under the E2 treatment. The biotin-labeled DNA
oligonucleotides (fragment of  270 to 138 on the SOD2 pro-
moter) were used for DNA pull down assay (DABA assay) as shown
in Fig. 3c, d. The results showed that E2 treatment signiﬁcantly
increased the binding afﬁnity of ERα and Sp1, and decreased theafﬁnity of ERβ and Sp3 on the indicated wild type fragment (GC
WT), while the fragment with GC box mutants (GC Mut, mutation
points of 153, 175, 187, 266, 251) decreased the binding
ability of Sp1, Sp3, ERα and ERβ, also, it largely diminished the
effect of E2. Finally, we did the chromatin immunoprecipitation
(ChIP) analysis using Sp1, Sp3, ERα and ERβ antibodies respec-
tively on the SOD2 promoter in the area of  300 to 100. Results
showed that E2 treatment decreased the association of Sp3 and
ERβ, but increased the association of Sp1 and ERα on the SOD2
promoter (see Fig. 3e).
ERβ/Sp1/Sp3 play a critical role in maintaining the basal level of
SOD2 expression, while ERα/Sp1 responses E2-induced SOD2 up-
regulation
We then evaluated the contribution role of Sp1, Sp3, ERα and
ERβ on the SOD2 expression using siRNA techniques. The above
Fig. 4. ERβ/Sp1/Sp3 play a critical role in maintaining basal level of SOD2 expression, while ERα/Sp1 responses E2-induced SOD2 up-regulation. Conditionally immortalized
HAECs were transfected by siRNA for NS (non-sense) control, Sp1 or Sp3, ERα or ERβ, plus luciferase reporter plasmids, then the cells were treated by either ethanol control
(CTL) or E2 for 2 days, and the cells were harvested for the measurement. (a) Western blots for Sp1 and Sp3 after siRNA treatment. (b) Western blots for ERα and ERβ after
siRNA treatment. (c, d) The above siRNA treated cells were harvested for SOD2 reporter activity assay (c) and mRNA analysis (d). n, Po0.05, vs CTL group; #, Po0.05, vs CTL in
iNS group. (e) Schematic model for E2-induced SOD2 up-regulation. n¼4, data are expressed as mean7SEM.
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ditionally immortalized HAECs, and the protein levels were con-
ﬁrmed by western blotting (see Fig. 4a, b). We then measured the
SOD2 luciferase reporter activity in those knockdown cells as
shown in Fig. 4c. We found that knockdown of ERβ and Sp3 sig-
niﬁcantly decreased SOD2 basal reporter activity, but the cells still
respond to E2-induced activation, even though the basal level is
much lower than wild type cells. Knockdown of ERα did not sig-
niﬁcantly decrease the basal reporter activity, but completely
abolished E2-induced SOD2 reporter activation. Sp1 knockdown
largely decreased the basal SOD2 reporter activity, also, it dimin-
ished the E2-mediated SOD2 reporter activation. We then mea-
sured the SOD2 mRNA expression from those knockdown cells, the
results were similar with SOD2 reporter activity (see Fig. 4d). This
suggests that Sp3 and ERβ play important role to maintain basal
SOD2 expression level, ERα responses E2-induced SOD2 up-reg-
ulation, while Sp1 not only responses basal expression, but also
responses E2-induced SOD2 up-regulation. Finally, in Fig. 4e, we
established the schematic model for E2-induced SOD2 expression.
In the absence of E2, the complex of ERβ and Sp3 have a higher
binding ability to GC-box than the complex of ERα and Sp1, this
keeps the basal level of SOD2 expression. While in the presence of
E2, activated ERα has a higher association with Sp1, this complex
competitively binds to the GC-box with ERβ/Sp3 and up-regulates
the SOD2 expression.E2-induced SOD2 up-regulation minimizes the ROS generation in
HAECs
The molecular consequence of E2-induced SOD2 up-regulation
was investigated. Conditionally immortalized HAECs were either
treated by control (CTL), E2, or infected by either SOD2 expression
(↑SOD2) or knockdown lentivirus (shSOD2) with the presence or
absence of E2 for 2 days, and the cells were used for further
analysis. In Fig. 5a, the SOD2 mRNA level was measured, we found
that E2 treatment or SOD2 lentivirus infection increased SOD2
expression signiﬁcantly, while shSOD2 lentivirus largely decreased
SOD2 expression regardless of the E2 treatment. Next, we mea-
sured the in vitro ROS generation as shown in Fig. 5b, the ROS
generation was decreased around 50% with the E2 treatment, and
the SOD2 lentivirus infection (↑SOD2) decreased the ROS genera-
tion by 53% compared to control group, which mimicked the
effect of E2. On the other hand, the SOD2 knockdown (shSOD2)
increased ROS by 1.7-fold regardless of the E2 presence, in-
dicating that the SOD2 expression plays a key role in the level of
ROS generation. Finally, we measured the 3-nitrotyrosine (3-NT)
accumulation through western blots. In Fig. 5c, d, the results
showed that E2 treatment signiﬁcantly decreased 3-NT accumu-
lation, and the SOD2 infection mimicked this effect, while SOD2
knockdown (shSOD2) treatment increased 3-NT accumulation by
1.6-fold, even in the presence of E2. These data suggest that E2-
induced SOD2 up-regulation minimizes the ROS generation in
HAECs.
Fig. 5. E2/ER-mediated SOD2 up-regulation minimizes the ROS generation in HAECs. Conditionally immortalized HAECs were treated by control (CTL), E2, or infected by
lentivirus for SOD2 expression (↑SOD2) or knockdown (shSOD2) in the presence or absence of E2 for 2 days, the cells were harvested for the analysis. (a) mRNA analysis of
SOD2 by qPCR. (b) ROS generation. (c) Quantitation results for 3-nitrotyrosine accumulation from western blotting. (d) Representative lanes for the 3-nitrotyrosine staining.
n, Po0.05, vs CTL group. n¼4, data are expressed as mean7SEM.
Z. Liu et al. / Redox Biology 3 (2014) 88–99 95Tie2-driven SOD2 lentivirus infection on vascular wall speciﬁcally and
efﬁciently modulates the SOD2 activity in endothelial cells
In order to further conﬁrm our ﬁndings that E2-induced SOD2
up-regulation has a vasculoprotective effect in endothelial cells,
the HFD treated mice were infected by SOD2 expression (↑SOD2)
or knockdown (shSOD2) lentivirus through tail vein injection, and
the SOD2 expression was measured. In Fig. 6a, the mouse en-
dothelial cells (MECs) from the heart and aorta were isolated using
Laser Capture Microdissection (LCM) for the mRNA analysis, the
results showed that the removal of E2 through OVX surgery sig-
niﬁcantly decreased the expression of SOD2 by 2-fold compared
to the Sham/CTL mice, the E2 treatment on those OVX mice re-
stored the SOD2 expression, while the SOD2 lentivirus infection of
those OVX mice signiﬁcantly increased SOD2 expression by 1.6-
and 1.8-fold respectively compared to Sham/CTL mice. On the
other hand, the shRNA SOD2 knockdown (shSOD2) decreased the
basal SOD2 expression for more than 4-fold compared to the
Sham/CTL mice, and the E2 treatment had no effect on SOD2 ex-
pression as long as SOD2 was knocked down. We also measured
the SOD2 mRNA expression from other tissues, including heart,aorta, live, kidney and hypothalamus as shown in Fig. 6b, we found
that OVX surgery decreased SOD2 expression by 50% in those
tissues, and the E2 treatment (from OVX/E2 group) signiﬁcantly
increased the SOD2 expression in all the tissues compared to OVX/
CTL group, neither SOD2 expression (↑SOD2) nor SOD2 knock-
down (shSOD2) treatment alone had any effect on the SOD2 ex-
pression, while the treatment of SOD2 knockdown plus E2 treat-
ment (OVX/shSOD2/E2) signiﬁcantly increased the SOD2 expres-
sion. It is interesting that we observed signiﬁcant changes of SOD2
expression in MECs isolated from both heart and aorta with the
lentivirus infection, while there were no signiﬁcant changes from
the whole heart, aorta and other tissues, this may be explained by
the fact that the percentage of endothelial cells from the whole
tissue is very low, and the expression changes from such a small
percentage of endothelial cells cannot be distinguished from the
whole tissue. Our data suggest that Tie2-driven SOD2 lentivirus
infection is efﬁcient and speciﬁc. We then investigated the SOD2
activity from cultured mice endothelial cells (MECs) that were
isolated from the heart and aorta. In Fig. 6c, OVX surgery sig-
niﬁcantly decreased SOD2 activity by 2-fold, the E2 treatment
normalized this effect, and the SOD2 infection (OVX/E2) largely
Fig. 6. Endothelium-speciﬁc delivery of SOD2 expression on vascular wall mimics E2-induced minimized ROS generation, and the SOD2 knockdown totally diminishes E2-
induced effect. (a) Treated mice were sacriﬁced, the mouse endothelial cells (MECs) were isolated by laser capture microdissection, and the SOD2 mRNA level was measured,
n¼5. (b) The treated mice were sacriﬁced and the related tissues, including heart, aorta, liver, kidney and hypothalamus were isolated for the analysis of SOD2 mRNA, n¼4.
(c) The mouse endothelial cells (MECs) from the heart and aorta were isolated and cultured for in vitro analysis of SOD2 activity, n¼4. (d) The whole aortas from treated mice
were isolated for in vivo superoxide release analysis, n¼6. n, Po0.05, vs sham/CTL group; #, P o 0.05, vs OVX/CTL group. Data are expressed as mean7SEM.
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(Sham/CTL), while the SOD2 knockdown (shSOD2) signiﬁcantly
decreased SOD2 expression by 4-fold regardless of the E2 pre-
sence, indicating that the infection of SOD2 lentivirus is efﬁcient in
modulating the SOD2 activity.
SOD2 lentivirus infection mimics the E2 treatment with minimized
superoxide anion release in the aorta
We investigated the effect of SOD2 lentivirus infection on the
ROS generation from those aortas. In Fig. 6d, the in vivo superoxide
anion (O2) release from the whole aorta was measured. The OVX
surgery increased the ROS generation by more than 2-fold com-
pared to Sham/CTL mice, and the E2 treatment or SOD2 lentivirus
infection (↑SOD2) restored OVX-induced ROS generation. On the
other hand, the SOD2 knockdown in OVX-treated mice (OVX/
shSOD2) also signiﬁcantly increased superoxide release despite
the E2 treatment compared to OVX treatment (OVX/CTL). Our data
indicate that the E2 modulates the ROS generation through the
regulation of SOD2 expression.
Tie2-driven lentivirus Infection of SOD2 on the vascular wall ame-
liorates the E2 deﬁciency-induced mitochondrial dysfunction and
vascular damage, while SOD2 knockdown partly diminishes the E2
effect
In order to evaluate the effect of E2 and the SOD2 manipulation
on the vascular wall, the MECs were isolated and cultured for thein vitro analysis. We measured several markers to evaluate the
mitochondrial function, including the intracellular ATP level, the
mitochondria membrane potential (MMP,ΔΨm) and the caspase-3
activity as shown in Fig. 7a, b and c, respectively. The results
showed that OVX surgery signiﬁcantly decreased the intracellular
ATP level, the mitochondrial membrane potential, and increased
the caspase-3 activity compared to control group (Sham/CTL), this
effect was completely restored by the E2 treatment, while the
SOD2 infection (↑SOD2) can only partly restore this effect. Fur-
thermore, the OVX-induced mitochondria dysfunction was wor-
sened by the shSOD2 knockdown, while the E2 treatment on OVX/
SOD2 knockdown mice (OVX/shSOD2/E2) signiﬁcantly amelio-
rated the effect, but again, cannot completely restore to normal
(Sham/CTL), indicating that E2-induced SOD2 plays important
vasculoprotective role, while some other factors may be also in-
volved in this process. Finally, the vessel tension of the vascular
ring was measured to evaluate the effect of the E2 treatment and
the SOD2 manipulation on the vascular wall. As shown in Fig. 7d, e
the acetylcholine-induced relaxation was signiﬁcantly decreased
by OVX surgery compared to control (CTL) group, and this effect
was restored by the E2 treatment, but partly restored by the SOD2
infection. On the other hand, the OVX-induced decreased relaxa-
tion was worsened by the SOD2 knockdown, and again, the E2
treatment can only partly restore this effect. This implies that
some other kinds of E2-induced factors may be also involved in
E2-deﬁciency induced vascular damage. Our results prove that the
E2-induced up-regulation of SOD2 in endothelial cells has a vas-
culoprotective effect.
Fig. 7. Endothelium-speciﬁc delivery of SOD2 expression on vascular wall ameliorates the mitochondrial dysfunction and vascular damage, while SOD2 knockdown partly
diminishes E2-induced effect. (a–c) The treated mice were sacriﬁced, the mouse endothelial cells (MECs) from the heart or aorta were isolated and cultured for in vitro
analysis. (a) Intracellular ATP levels; (b) relative mitochondrial membrane potential (ΔΨm); (c) caspase-3 activity. n¼5. (e, f) Treated mice were sacriﬁced, the aortas were
dissected for the vessel tension analysis. The rings were preconstricted with phenylephrine, and the acetylcholine (Ach, 1010–104 M) was injected at the plateau of the
phenylephrine-induced contraction. (e) The 104 M Ach-induced aorta ring relaxation. (f) The ach-induced aorta ring relaxation curves, n¼8–10. n, Po0.05, vs Sham/CTL
group; #, Po0.05, vs OVX/CTL group; ¶, Po0.05, vs OVX/shSOD2 group. Data are expressed as mean7SEM.
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Our study demonstrates that estrogen/estrogen receptor up-
regulates the SOD2 expression in endothelial cells with minimized
ROS generation and ameliorated cardiovascular damage. To our
knowledge, this is the ﬁrst time we have shown the potential
molecular mechanism for estrogen-mediated vasculoprotective
effect through up-regulation of speciﬁc gene on vascular wall.
Dominant role of endothelial cells in E2-induced vasculoprotective
action
Several cell populations in cardiovascular system, includ-
ing endothelial cells, vascular smooth muscle cells (VSMC)
and inﬂammatory immune cells (monocytes–macrophages, lym-
phocytes) play crucial role in the pathophysiology of athero-
sclerosis [4,34–36], while recent study shows that the endothelial
cells play a dominant role in E2-induced vasculoprotective action
[4,34]. In this study, we chose HAECs as in vitro cell model to in-
vestigate the mechanism of E2-induced gene expression. Also, in
the in vivo mice experiments, we used endothelium-speciﬁc Tie2-promoter to drive the SOD2 expression in a lentivirus vector, this
vector will only express the target genes in endothelial cells. On
realizing that the Tie2-promoter driven expression may have some
leaking effects, especially on hematopoietic lineages, we measured
the gene expression from other tissues. The results showed that
the SOD2 expression was only increased in endothelial cells from
the heart and aorta, showing no increase in liver, kidney and hy-
pothalamus (see Fig. 6a, b), indicating that Tie2 driven lentivirus
infection is sufﬁcient. This can be explained by the recent ﬁnding
that endothelial ERα plays a key role on the E2-induced ather-
oprotective effect, while the hematopoietic ERα is dispensable [4].
Role of ERα/β and Sp1/Sp3 in E2-induced SOD2 expression
E2 has been reported to have an antioxidant effect, it protects
against the oxidation of LDL, modulates the antioxidant gene ex-
pression etc. [37,38], while the exact mechanism still needs to be
fully understood. Here, we have identiﬁed a detailed molecular
mechanism for E2-induced SOD2 expression in endothelial cells,
up-regulated SOD2 expression minimizes ROS formation and 3-NT
accumulation, and subsequently ameliorate E2 deﬁciency-induced
Z. Liu et al. / Redox Biology 3 (2014) 88–9998vascular dysfunction. We have shown that the SOD2 expression is
mediated through E2-induced ERα/ERβ activation and subsequent
tethered Sp1/Sp3 binding to the GC box [39], where ERα responses
SOD2 activation, and ERβ responses SOD2 basal expression in
vascular endothelial cells, knockdown of ERα does not sig-
niﬁcantly decrease the SOD2 basal expression. This indicates that
both ERα and ERβ play important role in E2-induced vasculopro-
tective action [40,41]. In fact, many studies have shown that ERα
plays a dominant role in E2-induced vasculoprotective effect
[4,5,42], while using ERα and/or ERβ null mice, both ERs have
shown to be necessary and sufﬁcient for E2-mediated vascular
protection [43], and recently, ERβ has indicated that it plays a
crucial role in preventing early-stage atherosclerosis in ERα deﬁ-
cient mice [13]. The above contradictory observations can be ex-
plained well by our ﬁndings.
Vasculoprotective role of SOD2 and E2 in high-fat diet mice
Recent evidence indicates that reactive oxygen species (ROS)
produced in mitochondria contributes to the pathogenesis of car-
diovascular diseases [44,45], and the ROS plays many important
roles in triggering vascular damage, including oxidized LDL, ROS
induced DNA damage, mitochondrial dysfunction, impaired en-
zyme activity etc. [23,44,46]. In our study, we show that SOD2
expression in OVX mice can only partly restore E2-deﬁciency in-
duced mitochondrial dysfunction and vascular damage, indicating
that some other factors may also be involved in this process. In
fact, the E2 has been reported to play many important vasculo-
protective roles except its antioxidant effect, which include an
anti-inﬂammatory effect, regulation of feeding, food intake and
energy balance to prevent obesity [7,47], induction of eNOS ex-
pression [48], preventing the cell death and mitochondrial dys-
function [49], and preventing the fat accumulation in high-fat diet
mice etc. [7], all of them favor cardiovascular function [50]. In this
scenario, it is not surprising that E2-induced SOD2 expression can
only ameliorate E2-deﬁciency induced vascular damage, instead of
completely restoring that effect.
Clinical studies show that high-fat diet (HFD) impairs en-
dothelial function in humans [51], and HFD-induced obese mice
have been used to replicate the features of human obesity [52]
with many cardiovascular dysfunctions, including inﬂammation,
hypertrophy, ﬁbrosis, apoptosis, and endothelial dysfunction etc.
[53–55]. In our study, we used HFD mice as animal model to in-
vestigate the effect of E2 and SOD2 expression on the vascular
wall, our results show the signiﬁcant vascular damage reﬂected by
decreased vessel tension in OVX/SOD2 knockdown mice (OVX/
shSOD2) compared to the control group (Sham/CTL) as shown in
Fig. 6d, e, while we did not ﬁnd any signiﬁcant changes of hy-
pertension and atherosclerotic lesions [56] in our treated mice,
this is consistent with the previous ﬁndings that many obese pa-
tients develop hypertension, while 40–60% of them do not [57].
Altogether, our ﬁndings show that E2-induced vasculoprotec-
tive mechanism is partly due to E2-induced SOD2 expression in
endothelial cells. Gene therapy through infection of SOD2 on
vascular wall may ameliorate E2 deﬁciency-induced cardiovas-
cular damage in postmenopausal women.Acknowledgments
This work was supported by the 2013 International Science &
Technology Cooperation Project of Ministry of Education, China. #:
2013 DFA31400 (D.Y. and Z.L.). The authors are grateful to
Dr. Donald W. Pfaff (from Rockefeller University) and Dr. Anne M.Etgen (from Albert Einstein College of Medicine) for their kind
input on earlier drafts of this manuscript.References
[1] F. Grodstein, et al., Postmenopausal estrogen and progestin use and the risk of
cardiovascular disease, New England Journal of Medicine 335 (7) (1996)
453–461. http://dx.doi.org/10.1056/NEJM199608153350701 8672166.
[2] J.F. Arnal, et al., Estrogens in vascular biology and disease: where do we stand
today? Current Opinion in Lipidology 18 (5) (2007) 554–560. http://dx.doi.org/
10.1097/MOL.0b013e3282ef3bca 17885427.
[3] J. Vina, et al., Females live longer than males: role of oxidative stress, Current
Pharmaceutical Design 17 (36) (2011) 3959–3965. http://dx.doi.org/10.2174/
138161211798764942 22188448.
[4] A. Billon-Galés, et al., Endothelial estrogen receptor-alpha plays a crucial role
in the atheroprotective action of 17beta-estradiol in low-density lipoprotein
receptor-deﬁcient mice, Circulation 120 (25) (2009) 2567–2576. http://dx.doi.
org/10.1161/CIRCULATIONAHA.109.898445 19996016.
[5] J.B. Hodgin, et al., Estrogen receptor alpha is a major mediator of 17beta-es-
tradiol’s atheroprotective effects on lesion size in Apoe / mice, Journal of
Clinical Investigation 107 (3) (2001) 333–340. http://dx.doi.org/10.1172/
JCI11320 11160157.
[6] R.H. Karas, et al., Estrogen inhibits the vascular injury response in estrogen
receptor beta-deﬁcient female mice, Proceedings of the National Academy of
Sciences of the United States of America 96 (26) (1999) 15133–15136. http:
//dx.doi.org/10.1073/pnas.96.26.15133 10611350.
[7] S.A. Litwak, et al., Estradiol prevents fat accumulation and overcomes leptin
resistance in female high-fat diet miceEndocrinology 155 (11) (2014)
4447–4460. http://dx.doi.org/10.1210/en.2014-1342.
[8] J.E. Rossouw, et al., Postmenopausal hormone therapy and risk of cardiovas-
cular disease by age and years since menopause, Journal of American Medical
Association 297 (13) (2007) 1465–1477. http://dx.doi.org/10.1001/
jama.297.13.1465 17405972.
[9] J.A. Vita, J.F. Keaney Jr., Hormone replacement therapy and endothelial func-
tion: the exception that proves the rule? Arteriosclerosis, Thrombosis, and
Vascular Biology 21 (12) (2001) 1867–1869 11742856.
[10] R.K. Dubey, et al., Vascular consequences of menopause and hormone therapy:
importance of timing of treatment and type of estrogen, Cardiovascular Re-
search 66 (2) (2005) 295–306. http://dx.doi.org/10.1016/j.cardi-
ores.2004.12.012 15820198.
[11] M.E. Mendelsohn, R.H. Karas, The protective effects of estrogen on the cardi-
ovascular system, New England Journal of Medicine 340 (23) (1999)
1801–1811. http://dx.doi.org/10.1056/NEJM199906103402306 10362825.
[12] G.G. Kuiper, et al., Cloning of a novel receptor expressed in rat prostate and
ovary, Proceedings of the National Academy of Sciences of the United States
of America 93 (12) (1996) 5925–5930. http://dx.doi.org/10.1073/
pnas.93.12.5925 8650195.
[13] C. Zhao, K. Dahlman-Wright, J.Å Gustafsson, Estrogen signaling via estrogen
receptor {beta}, Journal of Biological Chemistry 285 (51) (2010) 39575–39579.
http://dx.doi.org/10.1074/jbc.R110.180109 20956532.
[14] O.I. Vivar, et al., Estrogen receptor beta binds to and regulates three distinct
classes of target genes, Journal of Biological Chemistry 285 (29) (2010)
22059–22066. http://dx.doi.org/10.1074/jbc.M110.114116 20404318.
[15] C.J. Park, et al., Genetic rescue of nonclassical ERalpha signaling normalizes
energy balance in obese Eralpha-null mutant mice, Journal of Clinical In-
vestigation 121 (2) (2011) 604–612. http://dx.doi.org/10.1172/JCI41702
21245576.
[16] Q. Wu, et al., Non-nuclear estrogen receptor signaling in the endothelium,
Journal of Biological Chemistry 286 (17) (2011) 14737–14743. http://dx.doi.
org/10.1074/jbc.R110.191791 21343284.
[17] R. O’Lone, et al., Genomic targets of nuclear estrogen receptors, Molecular
Endocrinology 18 (8) (2004) 1859–1875. http://dx.doi.org/10.1210/me.2003-
0044 15031323.
[18] P.J. Kushner, et al., Estrogen receptor pathways to AP-1, Journal of Steroid
Biochemistry and Molecular Biology 74 (5) (2000) 311–317. http://dx.doi.org/
10.1016/S0960-0760(00)00108-4 11162939.
[19] F. Delﬁno, W.H. Walker, Hormonal regulation of the NF-kappaB signaling
pathway, Molecular and Cellular Endocrinology 157 (1–2) (1999) 1–9
10619392.
[20] A. Suzuki, et al., Down-regulation of PROS1 gene expression by 17beta-es-
tradiol via estrogen receptor alpha (ERalpha)-Sp1 interaction recruiting re-
ceptor-interacting protein 140 and the corepressor–HDAC3 complex, Journal
of Biological Chemistry 285 (18) (2010) 13444–13453. http://dx.doi.org/
10.1074/jbc.M109.062430 20200160.
[21] A.L. Levonen, et al., Antioxidant gene therapy for cardiovascular disease:
current status and future perspectives, Circulation 117 (16) (2008) 2142–2150.
http://dx.doi.org/10.1161/CIRCULATIONAHA.107.718585 18427144.
[22] M. Ohashi, et al., MnSOD deﬁciency increases endothelial dysfunction in
ApoE-deﬁcient mice, Arteriosclerosis, Thrombosis, and Vascular Biology 26
(10) (2006) 2331–2336. http://dx.doi.org/10.1161/01.ATV.0000238347.77590.
c9 16873728.
Z. Liu et al. / Redox Biology 3 (2014) 88–99 99[23] M. El Assar, J. Angulo, L. Rodríguez-Mañas, Oxidative stress and vascular in-
ﬂammation in aging, Free Radical Biology and Medicine 65 (2013) 380–401.
http://dx.doi.org/10.1016/j.freeradbiomed.2013.07.003 23851032.
[24] M. Zanetti, et al., Gene transfer of manganese superoxide dismutase reverses
vascular dysfunction in the absence but not in the presence of atherosclerotic
plaque, Human Gene Therapy 12 (11) (2001) 1407–1416. http://dx.doi.org/
10.1089/104303401750298562 11485632.
[25] A.G. Bodnar, et al., Extension of life-span by introduction of telomerase into
normal human cells, Science 279 (5349) (1998) 349–352. http://dx.doi.org/
10.1126/science.279.5349.349 9454332.
[26] X.R. Jiang, et al., Telomerase expression in human somatic cells does not in-
duce changes associated with a transformed phenotype, Nature Genetics 21
(1) (1999) 111–114. http://dx.doi.org/10.1038/5056 9916802.
[27] R. Métivier, et al., Estrogen receptor-alpha directs ordered, cyclical, and
combinatorial recruitment of cofactors on a natural target promoter, Cell 115
(6) (2003) 751–763. http://dx.doi.org/10.1016/S0092-8674(03)00934-6
14675539.
[28] D. Yao, et al., Fatty acid-mediated intracellular iron translocation: a synergistic
mechanism of oxidative injury, Free Radical Biology and Medicine 39 (10)
(2005) 1385–1398. http://dx.doi.org/10.1016/j.freeradbiomed.2005.07.015
16257648.
[29] A.L. Moran, et al., Estradiol replacement reverses ovariectomy-induced muscle
contractile and myosin dysfunction in mature female mice, Journal of Applied
Physiology 102 (4) (2007) 1387–1393. http://dx.doi.org/10.1152/japplphy-
siol.01305.2006 17218423.
[30] K. Takeshita, et al., Critical role of endothelial Notch1 signaling in postnatal
angiogenesis, Circulation Research 100 (1) (2007) 70–78. http://dx.doi.org/
10.1161/01.RES.0000254788.47304.6e 17158336.
[31] E. Bossy-Wetzel, D.R. Green, Assays for cytochrome c release from mi-
tochondria during apoptosis, Methods Enzymology 322 (2000) 235–242. http:
//dx.doi.org/10.1016/S0076-6879(00)22024-7 10914021.
[32] D. Yao, et al., Chemiluminescence detection of superoxide anion release and
superoxide dismutase activity: modulation effect of Pulsatilla chinensis, Ana-
lytical and Bioanalytical Chemistry 379 (1) (2004) 171–177. http://dx.doi.org/
10.1007/s00216-004-2527-z 14985908.
[33] W. Zhang, et al., Endothelial cell-speciﬁc liver kinase B1 deletion causes en-
dothelial dysfunction and hypertension in mice in vivo, Circulation 129 (13)
(2014) 1428–1439. http://dx.doi.org/10.1161/CIRCULATIONAHA.113.004146
24637557.
[34] C.K. Glass, J.L. Witztum, Atherosclerosis. The road ahead, Cell 104 (4) (2001)
503–516. http://dx.doi.org/10.1016/S0092-8674(01)00238-0 11239408.
[35] P. Libby, Inﬂammation in atherosclerosis, Nature 420 (6917) (2002) 868–874.
http://dx.doi.org/10.1038/nature01323 12490960.
[36] C. Weber, A. Zernecke, P. Libby, The multifaceted contributions of leukocyte
subsets to atherosclerosis: lessons from mouse models, Nature Reviews Im-
munology 8 (10) (2008) 802–815. http://dx.doi.org/10.1038/nri2415 18825131.
[37] G.T. Shwaery, J.A. Vita, J.F. Keaney Jr., Antioxidant protection of LDL by phy-
siological concentrations of 17 beta-estradiol. Requirement for estradiol
modiﬁcation, Circulation 95 (6) (1997) 1378–1385. http://dx.doi.org/10.1161/
01.CIR.95.6.1378 9118503.
[38] K.A. Baltgalvis, et al., Estrogen regulates estrogen receptors and antioxidant
gene expression in mouse skeletal muscle, PLOS One 5 (4) (2010) e10164. http:
//dx.doi.org/10.1371/journal.pone.0010164 20405008.
[39] S. Safe, K. Kim, Nuclear receptor-mediated transactivation through interaction
with sp proteins, Progress in Nucleic Acid Research and Molecular Biology 77
(2004) 1–36. http://dx.doi.org/10.1016/S0079-6603(04)77001-4 15196889.
[40] J. Lin, et al., Estrogen receptor-beta activation results in S-nitrosylation of
proteins involved in cardioprotection, Circulation 120 (3) (2009) 245–254.
http://dx.doi.org/10.1161/CIRCULATIONAHA.109.868729 19581491.
[41] A. Foryst-Ludwig, et al., Metabolic actions of estrogen receptor beta (ERbeta)
are mediated by a negative cross-talk with PPARgamma, PLoS Genetics 4 (6)
(2008)e1000108http://dx.doi.org/10.1371/journal.pgen.1000108.[42] A. Billon-Galés, et al., The transactivating function 1 of estrogen receptor alpha
is dispensable for the vasculoprotective actions of 17beta-estradiol, Proceed-
ings of the National Academy of Sciences of the United States of America 106
(6) (2009) 2053–2058. http://dx.doi.org/10.1073/pnas.0808742106 19188600.
[43] J.F. Couse, K.S. Korach, Estrogen receptor null mice: what have we learned and
where will they lead us? Endocrine Reviews 20 (3) (1999) 358–417. http://dx.
doi.org/10.1210/edrv.20.3.0370 10368776.
[44] J. Gutierrez, et al., Free radicals, mitochondria, and oxidized lipids: the
emerging role in signal transduction in vascular cells, Circulation Research 99
(9) (2006) 924–932. http://dx.doi.org/10.1161/01.RES.0000248212.86638.e9
17068300.
[45] A.K. Doughan, D.G. Harrison, S.I. Dikalov, Molecular mechanisms of angio-
tensin II-mediated mitochondrial dysfunction: linking mitochondrial oxida-
tive damage and vascular endothelial dysfunction, Circulation Research 102
(4) (2008) 488–496. http://dx.doi.org/10.1161/CIRCRESAHA.107.162800
18096818.
[46] S.W. Ballinger, et al., Hydrogen peroxide- and peroxynitrite-induced mi-
tochondrial DNA damage and dysfunction in vascular endothelial and smooth
muscle cells, Circulation Research 86 (9) (2000) 960–966. http://dx.doi.org/
10.1161/01.RES.86.9.960 10807868.
[47] J. Hong, et al., Differential susceptibility to obesity between male, female and
ovariectomized female mice, Nutrition Journal 8 (2009) 11. http://dx.doi.org/
10.1186/1475-2891-8-11 19220919.
[48] K.L. Chambliss, P.W. Shaul, Estrogen modulation of endothelial nitric oxide
synthase, Endocrine Reviews 23 (5) (2002) 665–686. http://dx.doi.org/
10.1210/er.2001-0045 12372846.
[49] J. Guo, et al., 17beta-estradiol prevents cell death and mitochondrial dys-
function by an estrogen receptor-dependent mechanism in astrocytes after
oxygen-glucose deprivation/reperfusion, Free Radical Biology and Medicine 52
(11–12) (2012) 2151–2160. http://dx.doi.org/10.1016/j.free-
radbiomed.2012.03.005 22554613.
[50] D. Xing, et al., Estrogen and mechanisms of vascular protection, Arterio-
sclerosis, Thrombosis, and Vascular Biology 29 (3) (2009) 289–295. http://dx.
doi.org/10.1161/ATVBAHA.108.182279 19221203.
[51] K. Esposito, et al., Effect of a Mediterranean-style diet on endothelial dys-
function and markers of vascular inﬂammation in the metabolic syndrome: a
randomized trial, Journal of American Medical Association 292 (12) (2004)
1440–1446. http://dx.doi.org/10.1001/jama.292.12.1440 15383514.
[52] R. Buettner, J. Schölmerich, L.C. Bollheimer, High-fat diets: modeling the
metabolic disorders of human obesity in rodents, Obesity (Silver Spring) 15 (4)
(2007) 798–808. http://dx.doi.org/10.1038/oby.2007.608 17426312.
[53] E.D. Abel, S.E. Litwin, G. Sweeney, Cardiac remodeling in obesity, Physiological
Reviews 88 (2) (2008) 389–419. http://dx.doi.org/10.1152/physrev.00017.2007
18391168.
[54] M.H. Noyan-Ashraf, et al., A glucagon-like peptide-1 analog reverses the
molecular pathology and cardiac dysfunction of a mouse model of obesity,
Circulation 127 (1) (2013) 74–85. http://dx.doi.org/10.1161/CIRCULATIONA-
HA.112.091215 23186644.
[55] J. Al Suwaidi, et al., Obesity is independently associated with coronary en-
dothelial dysfunction in patients with normal or mildly diseased coronary
arteries, Journal of the American College of Cardiology 37 (6) (2001)
1523–1528. http://dx.doi.org/10.1016/S0735-1097(01)01212-8 11345360.
[56] P.A. Bourassa, et al., Estrogen reduces atherosclerotic lesion development in
apolipoprotein E-deﬁcient mice, Proceedings of the National Academy of
Sciences of the United States of America 93 (19) (1996) 10022–10027. http:
//dx.doi.org/10.1073/pnas.93.19.10022 8816744.
[57] A. Must, et al., The disease burden associated with overweight and obesity,
Journal of American Medical Association 282 (16) (1999) 1523–1529. http:
//dx.doi.org/10.1001/jama.282.16.1523 10546691.
